Scinai Immunotherapeutics Ltd.
SCNI
Last
$1.18
Day
-2.5%
1y
-91.8%
5y
-94.4%
52w
-92.3%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-2343d
EMA 21
1.53
EMA 50
2.01
EMA 200
5.61
20d high
-54.7%
5y high
-98.9%
5y range
0th
Positions held
Your positionsSCNI isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-27
Hold
avoid
Signal
Strong Sell
Target
$1.53
Stop
$0.94
Stop distance
20.3%
Target vs last
+29.7%
Fundamentals
| Market cap | $1.64M | Enterprise value | $7.24M | Trailing P/E | 0.04 | Forward P/E | — |
| PEG | — | Price / book | 0.11 | Beta | 2.13 | Dividend yield | 0.00% |
| Revenue growth | 146.0% | Earnings growth | — | Gross margin | -2.5% | Operating margin | -4.7% |
| Profit margin | -1.7% | ROE | -26.5% | ROA | -36.2% | Debt / equity | 0.31 |
| Current ratio | 1.56 | Free cash flow | -$3.66M | Analyst recommendation | none | Mean target | — |
| 52w high | $15.65 | 52w low | $1.06 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.5M | $0.5M | $0.2M | $0.6M |
| Op margin | -466.5% | -504.5% | -1173.8% | -267.6% |
| Net income | -$2.0M | $3.6M | -$2.6M | -$1.6M |
| Gross margin | -272.2% | -228.6% | -801.1% | 38.9% |
| Gross profit | -$1.3M | -$1.1M | -$1.5M | $0.2M |
| Operating income | -$2.1M | -$2.5M | -$2.2M | -$1.6M |
- Revenue -6% vs prior quarter ($0.5M vs $0.5M).
- Gross margin -272.2% (was -228.6% prior quarter).
- Operating margin expanded to -466.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.3M | $0.7M | $0.0M | $0.0M | — |
| Op margin | -575.3% | -1312.8% | — | — | — |
| Net income | -$8.3M | $4.8M | -$6.5M | -$5.8M | — |
| Gross margin | -202.3% | -88.1% | — | — | — |
| Gross profit | -$2.7M | -$0.6M | $0.0M | $0.0M | — |
| Operating income | -$7.5M | -$8.6M | -$9.7M | -$11.1M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-21 · Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-09-08 · Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
2026-08-24 · Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
Price (daily)
Full chart · RSI · MACD · patternsSCNI · daily-36.6% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin